This book defines issues facing previvors and survivors of breast and ovarian cancer. Including information about genetic counseling and testing, preventive surgery, and fertility and family planning, as well as explanations of health insurance coverage and laws protecting genetic privacy, this title tackles the challenges of living in a high-risk body.

The most comprehensive guide available on hereditary cancers, from understanding risk, prevention, and genetic counseling and testing to treatment, quality of life, and more. Up to 10 percent of cancers are caused by inherited mutations in specific genes. Finding out that you or your loved ones may be at increased risk of developing cancer because of a genetic mutation raises a lot of questions: Is cancer inevitable? Is there anything I should do differently in my life? Will my children also be at higher risk of cancer? Should I have preemptive treatments or surgery? This comprehensive guide provides answers to these questions and more. Written by three passionate patient advocates, this book is a compilation of the trusted information and support provided for more than two decades by Facing Our Risk of Cancer Empowered (FORCE), the de facto voice of the hereditary cancer community. Combining the latest scientific research with national guidelines, expert advice, and compelling patient stories, the book offers previvors (those who have a mutation but have never been diagnosed), survivors, and their families the guidance they need to face the unique physical and emotional challenges of living in a high-risk body. An ideal resource for genetic counselors, physicians, nurses, advocates, and others who support and care for the hereditary cancer community, Living with Hereditary Cancer Risk also provides coverage of • signs of inherited cancer risk in a family; • the value of genetic counseling and testing; • mutations in BRCA, Lynch Syndrome, and other genes that elevate cancer risk; • risk-reducing strategies; • traditional treatments and newer personalized approaches, including immunotherapies and PARP inhibitors; • nationally recommended guidelines for prevention, early detection, and treatment; • insurance coverage and discrimination protections; and • coping with sexual health, fertility, menopause, and other quality of life issues.

The first guide to all surgical and nonsurgical options for women with a high risk for breast cancer. Advances in genetic testing and risk assessment have changed the face of medicine, but with them has come a Pandora's box of dilemmas. Imagine discovering you had a significant risk for developing breast cancer. What would you do? Through the incredible true stories of five young friends, as well as interviews with more than seventy top breast cancer experts, health writer Dina Roth Port addresses the universal questions of women everywhere who have watched family members suffer from the disease and wondered, "Am I next?" Full of practical information, Previvors is the first comprehensive book to guide women through the difficult process of determining their risk, weighing the options, and coping with the emotions of deciding to undergo surgery. Readers will learn: •The pros and cons of getting tested for the BRCA gene •How to decide between surgical or nonsurgical options •The latest research in breast cancer surveillance •The advanced new world of breast reconstruction •How to overcome body image and sex issues post-surgery, and more From navigating health insurance coverage to finding the right medical team, Previvors is an invaluable resource for women facing decisions about their risk and future health. Watch a Video

This highly informative and clearly written book presents the basic science and the latest data on hereditary breast and ovarian cancer (HBOC) to provide an up-to-date and holistic overview of the disease. It starts off by presenting the molecular mechanisms, genetic testing and counseling, and variants of unknown significance (VUS) to help readers understand the contemporary interpretation of the disease. Further chapters focus on the surveillance, diagnosis and treatment, including chemoprevention, risk reduction and drug development based on molecular mechanisms. It also includes a chapter on the latest findings from the HBOC database, ethical issues and the parp inhibitors, and discusses innovative thinking to manage and understand the disease. Hereditary Breast and Ovarian Cancer - Molecular Mechanism and Clinical Practice offers breast surgeons, medical oncologists, gynecological oncologists and genetic counselors a comprehensive overview of the disease. Providing insights into recent scientific findings and further avenues for investigation, it is also a thought-provoking and informative read for researchers and scholars.

This book shares cutting-edge evidence on Hereditary Breast and Ovarian Cancer (HBOC) treatment, delivering facts on breast cancer, gynecologic oncology, and basic research to contribute to clinicians' practices. Each chapter presents the latest clinical techniques, basic experimental results, and the best-chosen research findings. The book is based on the works presented at the Japanese Organization of Hereditary Brest and Ovarian Cancer (JOHBOC) and a special chapter delivers a study based on the extensive data from the Japanese HBOC patients registered in the society's database, presenting novel evidence for further advancement in the field. The practice for HBOC has been rapidly increasing due to the clinical development of poly(ADP-ribose) polymerase inhibitors and the spread of companion diagnostics. In addition, the insurance coverage of a part of HBOC treatment raised social awareness in Japan, and the book illustrates not only clinical efforts but also issues related to the social system and the efforts of the association of related organizations. Hereditary Breast and Ovarian Cancer – Annual meeting of JOHBOC will be of interest to breast surgeons, obstetricians and gynecologists, pancreatic cancer surgeons, and urologists engaged in HBOC treatment through the implementation of companion diagnostics for PARP inhibitors administration. Also, physicians occupied in genetic medicine who perform genetic testing and medical staff practicing HBOC will find this book insightful. It is also for HBOC patients and their families, medical administrators in the social system of HBOC practice. Editors and authors hope to contribute to the equalization and widespread of HBOC practice and serve as a foundation for future advances in the disease's treatment and medical practice.